This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
T-VEC virotherapy yielded complete responses in injected lesions in 46% of patients in a phase I trial.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on January 29, 2021
doi: 10.1158/2159-8290.CD-RW2021-011
Oncolytic Virotherapy Shows Promise for Cutaneous B-cell Lymphoma
Jump to section
Advertisement